BOFAS News & Events

This pages lists all the latest news and upcoming events.

 

To access 'Foot Print' (the BOFAS Bulletin) please click here (members only)

 

Latest News

EFAS Lyon 2021 - Hybrid Annual Meeting

October 21-22-23 - Combined Face to Face and Virtual Meeting

The EFAS Congress Lyon 2021 will be the first hybrid congress from the European Foot and Ankle Society. 

EFAS hopes BOFAS members and others will join them in person for 3 amazing days of congress, to meet each other and exchange ideas, but in the current climate going abroad might still be difficult. EFAS would therefore like to extend the opportunity for all to be part of the congress by going HYBRID for the first time. 

Annual Meeting 2021 - Recap

The 2021 Annual Meeting is over, but click here if you missed it!

We hope you enjoyed the 2021 Virtual Annual meeting, but if you could not make it, it's available for members free of charge! Follow the link to view the programme and recordings. 

123456789

 

BOFAS Hosted Events

Courses organised by BOFAS
 

 

BOFAS Affiliated Courses

Courses by organisations with an affiliation to BOFAS
 

Other External Events / Courses

Independant courses organised by other organisations not directly affiliated with BOFAS, but which BOFAS members may find of value.
 
Togay Koç
/ Categories: Abstracts, 2015, Podium

Malignant bone tumours of the foot: a 30 year experience

A. Ramasamy, N. Bali, S. Evans, R. Grimer

Introduction: Bone tumours of the foot are rare, representing 3-6% of all bone tumours. Of these 15-25% are thought to be malignant. Obtaining clear surgical margins remains an important factor in improving outcome from tumours. However, the anatomical complexity of the foot can lead to an inadequate resection, particularly if the operating surgeon is attempting to preserve function. The aim of this paper is to identify the clinical course of patients suffering from malignant bone tumours of the foot.

Method: A prospective tumour registry over a 30 yr period was used to identify patients with a malignant bone tumour of the foot. Patient demographics along with the site of primary malignancy, region of the foot involved and clinical management were recorded.

Results: 70 patients with a malignant foot tumour were identified. 25(35%) were chondrosarcomas, 20 Ewings Sarcoma, 10 Osteosarcoma and 15 were metastatic lesions. Of those diagnosed with a primary bone tumour, 8(14.5%) were referred following a “whoops” procedure. The median length of symptoms prior to diagnosis was 52 weeks. The most common regions affected were the 1st Ray (31%) and Calcaneus (22%). The mainstay of treatment involved either Ray or Below Knee Amputation in 70% of cases. 11 patients developed either local recurrence or metastatic disease.

Conclusion: We present the largest single centre review of malignant bone tumours affecting the foot. Our series confirms that patients often have to suffer with protracted symptoms prior to the establishment of the correct diagnosis. The variety of differential diagnoses may explain the long delay in diagnosis. Worryingly, 14.5% of the primary bone malignancies in our series underwent a “whoops” procedure. This highlights further that physicians need to maintain a high index of suspicion when treating a patient with foot symptoms, even when the symptoms may be protracted.

Print
878